17:30 EST Cellectar Biosciences (CLRB) trading resumes
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- Cellectar Biosciences reports strategic reprioritization, reduces headcount 60%
- Cellectar Biosciences trading halted, news pending
- Cellectar Biosciences transferred with Buy rating at Ladenburg
- Cellectar Biosciences price target lowered to $12 from $14 at Oppenheimer
- Cellectar Biosciences Reports Q3 2024 Financial Results
Questions or Comments about the article? Write to editor@tipranks.com